Actively Recruiting
Pregnancy Outcomes in Normotensive VS stage1 Hypertension: a Prospective Observational Study
Led by FANG HE · Updated on 2024-07-03
626
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In 2017, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines built on evidence that elevated blood pressure increases cardiovascular mortality in the general population, Reclassification of BP; however, these diagnostic definitions do not include pregnant women, and whether newly diagnosed stage 1 hypertension affects pregnancy complications remains unclear. In this study, the combination of maternal factors, MAP and PLGF was used to comprehensively analyze the risk factors of preeclampsia through the "Bayesian rule" developed by the British Fetal Medicine Foundation (FMF). According to the guidelines and consensus, the pregnant women were considered to be at high risk when the calculated risk was higher than 1% of the population. To compare the pregnancy outcomes of women with normal blood pressure in the first trimester and stage 1 hypertension in different risk groups, and to find out whether screening for preeclampsia can be omitted for women with normal blood pressure in the first trimester, while screening for preeclampsia should still be performed for women with stage 1 hypertension as an independent moderate risk factor, and finally to optimize the screening strategy for preeclampsia.
CONDITIONS
Official Title
Pregnancy Outcomes in Normotensive VS stage1 Hypertension: a Prospective Observational Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Single live fetus with normal nuchal translucency at 11-14+1 weeks of gestation
- Blood pressure below 140/90 mmHg before 14+1 weeks of gestation
- Plan to have prenatal examinations and delivery at the study hospital
- Signed informed consent
You will not qualify if you...
- Chronic hypertension
- Type 1 or type 2 diabetes
- Kidney disease
- Autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
FANG HE
Guangzhou, Guangdong, China, 510150
Actively Recruiting
Research Team
F
Fang He, M.D
CONTACT
Y
Yafei Wang, Master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here